19-11059871-G-T
Variant summary
Our verdict is Likely benign. The variant received -1 ACMG points: 0P and 1B. BP4
The NM_001387283.1(SMARCA4):c.4850G>T(p.Gly1617Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000235 in 1,613,826 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1617C) has been classified as Uncertain significance.
Frequency
Consequence
NM_001387283.1 missense
Scores
Clinical Significance
Conservation
Publications
- Coffin-Siris syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet, Illumina
- intellectual disability, autosomal dominant 16Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
- rhabdoid tumor predisposition syndrome 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
- uterine corpus sarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- familial rhabdoid tumorInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -1 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SMARCA4 | ENST00000646693.2 | c.4850G>T | p.Gly1617Val | missense_variant | Exon 34 of 36 | NM_001387283.1 | ENSP00000495368.1 | |||
| SMARCA4 | ENST00000344626.10 | c.4754G>T | p.Gly1585Val | missense_variant | Exon 33 of 35 | 1 | NM_003072.5 | ENSP00000343896.4 | ||
| SMARCA4 | ENST00000643549.1 | c.4760G>T | p.Gly1587Val | missense_variant | Exon 33 of 35 | ENSP00000493975.1 | ||||
| SMARCA4 | ENST00000541122.6 | c.4664G>T | p.Gly1555Val | missense_variant | Exon 33 of 35 | 5 | ENSP00000445036.2 | |||
| SMARCA4 | ENST00000643296.1 | c.4664G>T | p.Gly1555Val | missense_variant | Exon 32 of 34 | ENSP00000496635.1 | ||||
| SMARCA4 | ENST00000644737.1 | c.4664G>T | p.Gly1555Val | missense_variant | Exon 32 of 34 | ENSP00000495548.1 | ||||
| SMARCA4 | ENST00000589677.5 | c.4661G>T | p.Gly1554Val | missense_variant | Exon 33 of 35 | 5 | ENSP00000464778.1 | |||
| SMARCA4 | ENST00000643995.1 | c.4175G>T | p.Gly1392Val | missense_variant | Exon 30 of 32 | ENSP00000496004.1 | ||||
| SMARCA4 | ENST00000644963.1 | c.3404G>T | p.Gly1135Val | missense_variant | Exon 26 of 28 | ENSP00000495599.1 | ||||
| SMARCA4 | ENST00000644065.1 | c.3386G>T | p.Gly1129Val | missense_variant | Exon 25 of 27 | ENSP00000493615.1 | ||||
| SMARCA4 | ENST00000642350.1 | c.3248G>T | p.Gly1083Val | missense_variant | Exon 25 of 27 | ENSP00000495355.1 | ||||
| SMARCA4 | ENST00000643857.1 | c.3014G>T | p.Gly1005Val | missense_variant | Exon 23 of 25 | ENSP00000494159.1 | ||||
| SMARCA4 | ENST00000538456.4 | c.818G>T | p.Gly273Val | missense_variant | Exon 6 of 8 | 3 | ENSP00000495197.1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152228Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.0000201 AC: 5AN: 248556 AF XY: 0.00000743 show subpopulations
GnomAD4 exome AF: 0.0000239 AC: 35AN: 1461598Hom.: 0 Cov.: 32 AF XY: 0.0000248 AC XY: 18AN XY: 727068 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152228Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74372 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Rhabdoid tumor predisposition syndrome 2 Uncertain:2
This sequence change replaces glycine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 1617 of the SMARCA4 protein (p.Gly1617Val). This variant is present in population databases (rs148115492, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. ClinVar contains an entry for this variant (Variation ID: 238488). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt SMARCA4 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
not provided Uncertain:2
In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge
Intellectual disability, autosomal dominant 16 Uncertain:1
SMARCA4-related disorder Uncertain:1
The SMARCA4 c.4850G>T variant is predicted to result in the amino acid substitution p.Gly1617Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.010% of alleles in individuals of East Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/19-11170547-G-T). This variant has been listed as 'likely benign' or 'uncertain' in the ClinVar database (https://preview.ncbi.nlm.nih.gov/clinvar/variation/238488/). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.
Hereditary cancer-predisposing syndrome Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Rhabdoid tumor predisposition syndrome 2;C3553249:Intellectual disability, autosomal dominant 16;C4013716:Small cell carcinoma of the ovary, hypercalcemic type Other:1
Variant classified as Uncertain significance and reported on 06-15-2022 by Invitae. GenomeConnect-InvitaePIN assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at